Caribou Biosciences, Inc. CRBU 深 沪
已收盘 05-08 16:00:00 美东时间
1.94
+0.060
+3.19%
华盛通- 最 高1.985
- 今 开1.90
- 成交量 89.21万股
- 最 低 1.89
- 昨 收 1.88
- 总市值 19.14万
- 52周最高 3.535
- 市盈率 静 --
- 换手率 0.90%
- 52周最低 0.9179
- 委 比 -13.53%
- 总股本 9.87万
- 历史最高 32.645
- 量 比 0.74
- 振 幅 5.05%
- 历史最低 0.66
- 每 手 1
- 风险率 0.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Caribou Biosciences Q1 EPS $(0.26) Beats $(0.31) Estimate, Sales $2.397M Beat $2.241M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 39.53 percent increase over losses of $(0.43) per share
05-08 04:46
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
Caribou Biosciences Receives FDA's Regenerative Medicine Advanced Therapy Designation To CB-011 For Relapsed Or Refractory Multiple Myeloma
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine
03-31 20:02
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
Evercore ISI Group Maintains Outperform on Caribou Biosciences, Raises Price Target to $13
Evercore ISI Group analyst Jonathan Miller maintains Caribou Biosciences (NASDAQ:CRBU) with a Outperform and raises the price target from $11 to $13.
03-10 00:08
美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Clear Street Initiates Coverage On Caribou Biosciences with Buy Rating, Announces Price Target of $13
Clear Street analyst Bill Maughan initiates coverage on Caribou Biosciences (NASDAQ:CRBU) with a Buy rating and announces Price Target of $13.
02-03 05:27
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
Caribou Biosciences will host a panel discussion at the 67th ASH Annual Meeting to explore how vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, can expand access for patients with second-line large B cell lymphoma, particularly in community settings. The event, moderated by Tina Albertson, MD, PhD, will feature insights from leading physicians and discuss vispa-cel's safety, efficacy, and potential to improve treatment accessibility. Vispa-...
2025-12-01 21:05
Caribou Biosciences Q3 EPS $(0.30) Beats $(0.36) Estimate, Sales $2.198M Miss $2.650M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.2 percent. This is a 21.05 percent increase over losses of $(0.38) per share
2025-11-13 05:20
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
1. Caribou Biosciences报告了2025年第三季度财务结果，截至2025年9月30日拥有1.592亿美元现金、现金等价物和市场证券。 2. Vispa-cel在ANTLER 1期试验中显示疗效和安全性与自体CAR-T疗法相当，有望成为同类最佳异基因CAR-T疗法。 3. CB-011在CaMMouflage 1期试验中表现出深度和持久反应，成为治疗复发性多发性骨髓瘤的潜在最佳异基因CAR-T疗法。 4. 研发费用下降至2240万美元，管理费用下降至920万美元，净亏损扩大至2.7545亿美元。
2025-11-12 21:05
